Medicare Part D Offers GLP-1 Drugs for $50 Monthly

Eligible Medicare patients can now access weight loss medications at a significantly reduced monthly cost.

Updated on Oct. 22, 2026 in Weight Loss

Medicare Part D Offers GLP-1 Drugs for $50 Monthly

Live Poll

Do you believe current discount programs are doing enough to make essential medications affordable for you?

The Medicare Part D Bridge Program provides select GLP-1 medications at a reduced cost of $50 per month. This initiative aims to improve access for eligible patients struggling with the high list prices of these treatments.

Why it matters

The list price of medications like Wegovy can reach $1,300, creating significant financial barriers for patients. This program serves to lower costs for those who meet specific clinical criteria, helping to narrow the gap in treatment accessibility.

The Medicare Part D Bridge Program offers GLP-1 medications for $50 monthly, representing a 96% reduction from the $1,300 list price of medications like Wegovy. It remains unclear how long the program will continue to support this specific pricing model.

The details

The program functions by bypassing traditional retail list prices for eligible patients who require pharmacological support for weight management. Patients must maintain a BMI of 35 or higher, or a BMI between 27 and 34 with specific associated health conditions, to qualify for the pricing. Interested individuals must first consult with a physician to determine if they meet these medical criteria and to obtain a prescription, which is then processed through the program framework.

The Medicare Part D Bridge Program was launched a few months ago.

Health Landscape

This program operates within the established framework of Medicare Part D to address the widening gap between high pharmaceutical list prices and patient coverage. It represents a shift toward more direct manufacturer and payer cost-mitigation strategies for high-demand GLP-1 therapies.

If you are currently managing weight-related health concerns, it is worth discussing with your doctor whether you meet the clinical criteria for this program. You should also confirm if your current prescriptions are eligible for coverage before making any changes to your care plan.

The takeaway

The Bridge Program demonstrates the potential for significant cost reductions for patients facing high prices for GLP-1 medications. If you are interested in this option, start by scheduling an appointment with your physician to evaluate your eligibility based on your current BMI and health history.